Norway-based clinical-stage biotechnology company Ultimovacs (OSE:ULTI) announced on Monday that it has secured Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its UV1 cancer vaccine in mesothelioma, supported by positive results from the NIPU Phase II trial.
UV1 has also received ODD from the US Food and Drug Administration (FDA) for treating mesothelioma and malignant melanoma stages IIB to IV.
In the EU, ODD provides exclusive market rights for 10 years, clinical protocol assistance, centralised marketing authorisation and reduced regulatory fees.
Mesothelioma, often linked to asbestos exposure, lacks effective treatments, making UV1's approval significant. The NIPU trial demonstrated UV1's efficacy in combination with ipilimumab and nivolumab, showing improved overall survival without added toxicities.
Recently approved Fast Track designation from the FDA further accelerates UV1's path to approval, marking potentially significant progress in mesothelioma treatment.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review